Brokerages Anticipate Chimerix Inc (CMRX) Will Announce Earnings of -$0.44 Per Share

Wall Street brokerages predict that Chimerix Inc (NASDAQ:CMRX) will post earnings of ($0.44) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Chimerix’s earnings, with the highest EPS estimate coming in at ($0.42) and the lowest estimate coming in at ($0.46). Chimerix posted earnings of ($0.36) per share during the same quarter last year, which would suggest a negative year over year growth rate of 22.2%. The firm is scheduled to issue its next earnings results on Monday, August 6th.

On average, analysts expect that Chimerix will report full-year earnings of ($1.77) per share for the current financial year, with EPS estimates ranging from ($1.85) to ($1.64). For the next financial year, analysts expect that the firm will post earnings of ($1.71) per share, with EPS estimates ranging from ($2.00) to ($1.20). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that cover Chimerix.

Chimerix (NASDAQ:CMRX) last posted its earnings results on Monday, May 7th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.01. Chimerix had a negative return on equity of 31.97% and a negative net margin of 1,736.95%. The company had revenue of $0.79 million for the quarter, compared to analyst estimates of $1.12 million.

A number of research analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Chimerix in a report on Thursday, June 7th. ValuEngine upgraded Chimerix from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Zacks Investment Research lowered Chimerix from a “buy” rating to a “hold” rating in a report on Monday, May 7th. BidaskClub upgraded Chimerix from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 15th. Finally, Cowen restated a “hold” rating and issued a $6.00 target price on shares of Chimerix in a report on Thursday, March 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $7.08.

In other Chimerix news, insider M Michelle Berrey purchased 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 12th. The stock was bought at an average cost of $4.50 per share, with a total value of $45,000.00. Following the completion of the transaction, the insider now owns 325,256 shares of the company’s stock, valued at approximately $1,463,652. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ernest Mario sold 30,000 shares of the stock in a transaction that occurred on Wednesday, May 16th. The shares were sold at an average price of $4.79, for a total value of $143,700.00. Following the sale, the director now directly owns 12,905 shares of the company’s stock, valued at $61,814.95. The disclosure for this sale can be found here. Insiders have sold 130,368 shares of company stock valued at $616,495 over the last ninety days. 12.50% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Prosight Management LP purchased a new stake in shares of Chimerix during the fourth quarter valued at approximately $6,846,000. Ascend Capital LLC increased its position in shares of Chimerix by 96.9% during the fourth quarter. Ascend Capital LLC now owns 699,664 shares of the biopharmaceutical company’s stock valued at $3,240,000 after acquiring an additional 344,311 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Chimerix by 33.6% during the fourth quarter. Renaissance Technologies LLC now owns 259,152 shares of the biopharmaceutical company’s stock valued at $1,200,000 after acquiring an additional 65,192 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of Chimerix by 13.9% during the fourth quarter. Victory Capital Management Inc. now owns 256,424 shares of the biopharmaceutical company’s stock valued at $1,187,000 after acquiring an additional 31,340 shares during the last quarter. Finally, Two Sigma Investments LP increased its position in Chimerix by 87.3% in the fourth quarter. Two Sigma Investments LP now owns 224,439 shares of the biopharmaceutical company’s stock worth $1,039,000 after buying an additional 104,579 shares during the last quarter. 73.49% of the stock is owned by institutional investors.

Shares of Chimerix traded down $0.08, reaching $4.76, during trading hours on Tuesday, Marketbeat Ratings reports. The company had a trading volume of 684,363 shares, compared to its average volume of 230,215. Chimerix has a 12 month low of $4.17 and a 12 month high of $5.94.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply